Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease

Janssens Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis


  • Janssen has submitted MAA to EMA for an investigational Ebola vaccine regimen in two doses Ad26.ZEBOV, MVA-BN-Filo for the prevention of Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. In Sept’2019, EMA’s CHMP has granted an accelerated
  • The MAA is based on multiple preclinical, P-I, II & III studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children in 6,500+ volunteers across the US, EU and Africa
  • The vaccine regimen includes Ad26.ZEBOV as the first dose, based on Janssen’s AdVac technology and MVA-BN-Filo as the second dose, based on Bavarian Nordic’s MVA-BN technology and is administered ~8wks. later. Additionally, Janssen is working with WHO to register Ebola vaccine regimen in African countries

Click here to­ read full press release/ article | Ref: Janssen  | Image: The Boston Globe